MRI Screening Before Standard Tissue Plasminogen Activator Therapy Is Feasible and Safe
Open Access
- 1 September 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 36 (9) , 1939-1943
- https://doi.org/10.1161/01.str.0000177539.72071.f0
Abstract
Background and Purpose— MRI screening for thrombolytic therapy may improve patient selection. Alternatively, it may excessively delay treatment and thereby lead to worse outcomes. We hypothesized that times to treatment and outcomes in a stroke center with immediate MRI access and interpretation would not differ from those of the typical clinical practice.Keywords
This publication has 12 references indexed in Scilit:
- Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness StudyCMAJ : Canadian Medical Association Journal, 2005
- Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection ProtocolStroke, 2005
- The Desmoteplase in Acute Ischemic Stroke Trial (DIAS)Stroke, 2005
- Comparison of MRI and CT for Detection of Acute Intracerebral HemorrhageJAMA, 2004
- Are There Time-Dependent Differences in Diffusion and Perfusion Within the First 6 Hours After Stroke Onset?Stroke, 2004
- Early blood–brain barrier disruption in human focal brain ischemiaAnnals of Neurology, 2004
- Stroke Magnetic Resonance Imaging Is Accurate in Hyperacute Intracerebral HemorrhageStroke, 2004
- Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis eraAnnals of Neurology, 2003
- Early stroke treatment associated with better outcomeNeurology, 2000
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995